Monograph Details
|
|
Poisoning & Drug Dependence
> Addiction/dependence
|
|
REVIA |
| Manufacturer |
|
Duramed Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Opioid antagonist. |
| Generic Name |
|
Naltrexone HCl 50mg; scored tabs. |
| Indications |
|
Adjunct in treatment of alcohol or narcotic dependence. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Confirm 7–10 day opioid-free period, if questionable do Narcan challenge test (see literature). ≥18yrs: Alcoholism: 50mg daily. Narcotic dependence: Initially 25mg, if no withdrawal symptoms increase to 50mg daily; alternative dosing schedules: see literature. |
| Contraindications |
|
Concomitant opioids, current opioid dependence, or acute opioid withdrawal. Failed Narcan challenge test or (+) urine screen for opioids. Acute hepatitis. Liver failure. |
| Precautions |
|
Liver disease. Monitor liver function. Warn patients of danger of attempting to overcome opiate blockade. Severe renal dysfunction. Possible acute abstinence syndrome. Depression. Suicidal ideation. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Thioridazine increases sedation. Antagonizes opioids (eg, antitussives, antidiarrheals, analgesics). Disulfiram. |
| Adverse Reactions |
|
Hepatotoxicity, withdrawal reactions; others, see literature. |
| How Supplied |
|
Tabs—30, 100 |
|
|
|
|
